AMG National Trust Bank Invests $2.52 Million in Baxter International Inc. $BAX

Key Points

• AMG National Trust Bank initiated a $2.52 million position in Baxter International during the second quarter by purchasing 118,281 shares. Institutional investors collectively own 90.19% of BAX.
• Baxter reported quarterly earnings of $0.56 per share, exceeding estimates of $0.37, while revenue reached $2.96 billion and increased 5.3% year over year.
• Analysts have a consensus “Hold” rating, with an average price target of $22.45; several firms recently raised their targets, even as BAX opened at $26.66.

AMG National Trust Bank bought a new position in shares of Baxter International Inc. (NYSE:BAX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 118,281 shares of the medical instruments supplier's stock, valued at approximately $2,522,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Simplicity Wealth LLC acquired a new stake in Baxter International in the 2nd quarter valued at $340,000. Bank of New York Mellon Corp bought a new position in shares of Baxter International in the 2nd quarter valued at about $68,036,000. GAMMA Investing LLC grew its holdings in shares of Baxter International by 98.3% in the 2nd quarter. GAMMA Investing LLC now owns 33,909 shares of the medical instruments supplier's stock valued at $723,000 after acquiring an additional 16,809 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Baxter International by 552.2% in the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier's stock valued at $51,000 after acquiring an additional 2,043 shares during the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of Baxter International by 3.2% in the first quarter. Pacer Advisors Inc. now owns 41,709 shares of the medical instruments supplier's stock valued at $701,000 after acquiring an additional 1,295 shares during the last quarter. Institutional investors own 90.19% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wells Fargo & Company raised their price target on Baxter International from $19.00 to $23.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Citigroup upgraded Baxter International from a "sell" rating to a "neutral" rating and upped their price objective for the stock from $17.00 to $28.00 in a research note on Friday, July 31st. Barclays increased their price objective on Baxter International from $25.00 to $27.00 and gave the company an "overweight" rating in a report on Friday, May 1st. UBS Group raised their target price on shares of Baxter International from $19.00 to $25.00 and gave the company a "hold" rating in a research note on Tuesday, July 28th. Finally, TD Cowen boosted their target price on shares of Baxter International from $20.00 to $24.00 and gave the stock a "hold" rating in a report on Monday, July 27th. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $22.45.

Baxter International Stock Performance

BAX opened at $26.66 on Monday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. Baxter International Inc. has a 12-month low of $15.73 and a 12-month high of $30.00. The business has a 50 day moving average of $23.02 and a 200-day moving average of $20.13. The stock has a market cap of $13.79 billion, a price-to-earnings ratio of -12.88, a PEG ratio of 4.04 and a beta of 0.59.

Baxter International (NYSE:BAX - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The firm's revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, equities research analysts expect that Baxter International Inc. will post 2.04 earnings per share for the current year.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th. Baxter International's payout ratio is currently -1.93%.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source